Confirmatory Tests in the Diagnosis of Primary Aldosteronism

Abstract

Primary aldosteronism is the most common form of secondary hypertension and patients with hyperaldosteronism are more prone to premature cardiovascular complications compared to essential hypertensives. The diagnostic flow-chart for the diagnosis of PA is performed in three steps: a) screening; b) confirmation; and c) subtype differentiation. Instead of proceeding directly to subtype classification, the recently published Endocrine Society Guidelines recommend that patients with a positive ARR should undergo a confirmatory test, in order to definitively confirm or exclude the diagnosis of PA. The Guidelines recognize four testing procedures: oral sodium loading, saline infusion, fludrocortisone suppression, and captopril challenge. Herein we discuss the diagnostic protocols for these confirmatory tests and highlight both the advantages and contraindications and we discuss studies in which these confirmatory tests have been compared.

saline load - aldosterone - captopril test - fludrocortisone - hyperaldosteronism

References

• 1 Hiramatsu K, Yamada T, Yukimura Y, Komiya I, Ichikawa K, Ishihara M, Nagata H, Izumiyama T. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity: results in hypertensive patients.  Arch Intern Med. 1981;  141 1589-1593
• 2 Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, Gomez-Sanchez CE, Veglio F, Young Jr WF. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents.  J Clin Endocrinol Metab. 2004;  89 1045-1050
• 3 Kaplan NM. The current epidemic of primary aldosteronism: causes and consequences.  J Hypertens. 2004;  22 863-869
• 4 Mosso L, Carvajal C, González A, Barraza A, Avila F, Montero J, Huete A, Gederlini A, Fardella CE. Primary aldosteronism and hypertensive disease.  Hypertension. 2003;  42 161-165
• 5 Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension.  Hypertension. 2002;  40 892-896
• 6 Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young Jr WF, Montori VM. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline.  J Clin Endocrinol Metab. 2008;  93 3266-3281
• 7 Mulatero P, Bertello C, Verhovez A, Rossato D, Giraudo G, Mengozzi G, Limerutti G, Avenatti E, Tizzani D, Veglio F. Differential diagnosis of primary aldosteronism subtypes.  Curr Hypertens Rep. 2009;  11 217-223
• 8 Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourard JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism.  J Am Coll Cardiol. 2005;  45 1243-1248
• 9 Born-Frontsberg E, Reincke M, Rump LC, Hahner S, Diederich S, Lorenz R, Allolio B, Seufert J, Schirpenbach C, Beuschlein F, Bidlingmaier M, Endres S, Quinkler M. Participants of the German Conn's Registry. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry.  J Clin Endocrinol Metab. 2009;  94 1125-1130
• 10 Mulatero P, Milan A, Williams TA, Veglio F. Mineralocorticoid receptor blockade in the protection of target organ damage.  Cardiovasc Hematol Agents Med Chem.. 2006;  4 75-91
• 11 Mulatero P, Verhovez A, Morello F, Veglio F. Diagnosis and treatment of low-renin hypertension.  Clin Endocrinol (Oxf). 2007;  67 324-334
• 12 Fallo F, Veglio F, Bertello C, Sonino N, Della Mea P, Ermani M, Rabbia F, Federspil G, Mulatero P. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism.  J Clin Endocrinol Metab. 2006;  91 454-459
• 13 Fallo F, Della Mea P, Sonino N, Bertello C, Ermani M, Vettor R, Veglio F, Mulatero P. Adiponectin and insulin sensitivity in primary aldosteronism.  Am J Hypertens. 2007;  20 855-861
• 14 Maule S, Mulatero P, Milan A, Leotta G, Caserta M, Bertello C, Rabbia F, Veglio F. QT interval in patients with primary aldosteronism and low-renin essential hypertension.  J Hypertens. 2006;  24 2459-2464
• 15 Fallo F, Federspil G, Veglio F, Mulatero P. The metabolic syndrome in primary aldosteronism.  Curr Hypertens Rep. 2007;  9 106-111
• 16 Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, Sechi LA. Cardiovascular outcomes in patients with primary aldosteronism after treatment.  Arch Intern Med. 2008;  168 80-85
• 17 Rossi GP, Sechi LA, Giacchetti G, Ronconi V, Strazzullo P, Funder JW. Primary aldosteronism: cardiovascular, renal and metabolic implications.  Trends Endocrinol Metab. 2008;  19 88-90
• 18 Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel JM. A chimaeric 11β-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension.  Nature. 1992;  355 262-265
• 19 Stowasser M, Gordon RD. Primary aldosteronism: from genesis to genetics.  Trends Endocrinol Metab. 2003;  14 310-317
• 20 Sukor N, Mulatero P, Gordon RD, So A, Duffy D, Bertello C, Kelemen L, Jeske Y, Veglio F, Stowasser M. Further evidence for linkage of familial hyperaldosteronism type II at chromosome 7p22 in Italian as well as Australian and South American families.  J Hypertens. 2008;  26 1577-1582
• 21 Geller DS, Zhang J, Wisgerhof MV, Shackleton C, Kashgarian M, Lifton RP. J A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism.  Clin Endocrinol Metab. 2008;  93 3117-3123
• 22 Mulatero P. A new form of hereditary primary aldosteronism: familial hyperaldosteronism type III.  J Clin Endocrinol Metab. 2008;  93 2972-2974
• 23 Mulatero P, Dluhy RG, Giacchetti G, Boscaro M, Veglio F, Stewart PM. Diagnosis of primary aldosteronism: from screening to subtype differentiation.  Trends Endocrinol Metab. 2005;  16 114-119
• 24 Stowasser M, Gordon RD, Rutherford JC, Nikwan NZ, Daunt N, Slater GJ. Diagnosis and management of primary aldosteronism.  J Renin Angiotensin Aldosterone Syst. 2001;  2 156-169
• 25 Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, Veglio F. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism.  Hypertension. 2002;  40 897-902
• 26 Letavernier E, Peyrard S, Amar L, Zinzindohoué F, Fiquet B, Plouin PF. Blood pressure outcome of adrenalectomy in patients with primary hyperaldosteronism with or without unilateral adenoma.  J Hypertens. 2008;  26 1816-1823
• 27 Schirpenbach C, Seiler L, Maser-Gluth C, Beuschlein F, Reincke M, Bidlingmaier M. Automated chemiluminescence-immunoassay for aldosterone during dynamic testing: comparison to radioimmunoassays with and without extraction steps.  Clin Chem. 2006;  52 1749-1755
• 28 Pizzolo F, Corgnati A, Guarini P, Pavan C, Bassi A, Corrocher R, Olivieri O. Plasma aldosterone assays: comparison between chemiluminescence-based and RIA methods.  Clin Chem. 2006;  52 1431-1432
• 29 Stowasser M, Gordon RD. Aldosterone assays: an urgent need for improvement.  Clin Chem. 2006;  52 1640-1642
• 30 Stowasser M, Gordon RD, Gunasekera TG, Cowley DC, Ward G, Archibald C, Smithers BM. High rate of detection of primary aldosteronism, including surgically treatable forms, after ‘non-selective’ screening of hypertensive patients.  J Hypertens. 2003;  21 2149-2157
• 31 Mosso LM, Carvajal CA, Maiz A, Ortiz EH, Castillo CR, Artigas RA, Fardella CE. A possible association between primary aldosteronism and a lower beta-cell function.  J Hypertens. 2007;  25 2125-2130
• 32 Sukor N, Gordon RD, Ku YK, Jones M, Stowasser M. Role of unilateral adrenalectomy in bilateral primary aldosteronism: a 22-year single center experience.  J Clin Endocrinol Metab. 2009;  94 2437-2445
• 33 Mulatero P, Milan A, Fallo F, Regolisti G, Pizzolo F, Fardella C, Mosso L, Marafetti L, Veglio F, Maccario M. Comparison of confirmatory tests for the diagnosis of primary aldosteronism.  J Clin Endocrinol Metab. 2006;  91 2618-2623
• 34 Giacchetti G, Mulatero P, Mantero F, Veglio F, Boscaro M, Fallo F. Primary aldosteronism, a major form of low renin hypertension: from screening to diagnosis.  Trends Endocrinol Metab. 2008;  19 104-108
• 35 Sechi LA, Di Fabio A, Bazzocchi M, Uzzau A, Catena C. Intrarenal hemodynamics in primary aldosteronism before and after treatment.  J Clin Endocrinol Metab. 2009;  94 1191-1197
• 36 Reincke M, Rump LC, Quinkler M, Hahner S, Diederich S, Lorenz R, Seufert J, Schirpenbach C, Beuschlein F, Bidlingmaier M, Meisinger C, Holle R, Endres S. Participants of German Conn's Registry. Risk factors associated with a low glomerular filtration rate in primary aldosteronism.  J Clin Endocrinol Metab. 2009;  94 869-875
• 37 Loh KC, Koay ES, Khaw MC, Emmanuel SC, Young Jr WF. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore.  J Clin Endocrinol Metab. 2000;  85 2854-2859
• 38 Young WF. Primary aldosteronism: renaissance of a syndrome.  Clin Endocrinol (Oxf). 2007;  66 607-618
• 39 Williams JS, Williams GH, Raji A, Jeunemaitre X, Brown NJ, Hopkins PN, Conlin PR. Prevalence of primary hyperaldosteronism in mild to moderate hypertension without hypokalaemia.  J Hum Hypertens. 2006;  20 129-136
• 40 Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F. PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients.  J Am Coll Cardiol. 2006;  48 2293-2300
• 41 Lyons DF, Kem DC, Brown RD, Hanson CS, Carollo ML. Single dose captopril as a diagnostic test for primary aldosteronism.  J Clin Endocrinol Metab. 1983;  57 892-896
• 42 Agharazii M, Douville P, Grose JH, Lebel M. Captopril suppression versus salt loading in confirming primary aldosteronism.  Hypertension. 2001;  37 1440-1443
• 43 Castro OL, Yu X, Kem DC. Diagnostic value of the post-captopril test in primary aldosteronism.  Hypertension. 2002;  39 935-938
• 44 Mulatero P, Bertello C, Garrone C, Rossato D, Mengozzi G, Verhovez A, Fallo F, Veglio F. Captopril test can give misleading results in patients with suspect primary aldosteronism.  Hypertension. 2007;  50 e26-e27
• 45 Rossi GP, Belfiore A, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Palumbo G, Rizzoni D, Rossi E, Agabiti-Rosei E, Pessina AC, Mantero F. Primary Aldosteronism Prevalence in Italy Study Investigators. Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma.  Hypertension. 2007;  50 424-431
• 46 Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan.  Hypertens Res. 2004;  27 193-202
• 47 Hirohara D, Nomura K, Okamoto T, Ujihara M, Takano K. Performance of the basal aldosterone to renin ratio and of the renin stimulation test by furosemide and upright posture in screening for aldosterone-producing adenoma in low renin hypertensives.  J Clin Endocrinol Metab. 2001;  86 4292-4298
• 48 Giacchetti G, Ronconi V, Lucarelli G, Boscaro M, Mantero F. Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol.  J Hypertens. 2006;  24 737-745
• 49 Wu VC, Chang HW, Liu KL, Lin YH, Chueh SC, Lin WC, Ho YL, Huang JW, Chiang CK, Yang SY, Chen YM, Wang SM, Huang KH, Hsieh BS, Wu KD. TAIPAI Study Group . Primary aldosteronism: diagnostic accuracy of the losartan and captopril tests.  Am J Hypertens. 2009;  22 821-827
• 50 Schirpenbach C, Seiler L, Maser-Gluth C, Rüdiger F, Nickel C, Beuschlein F, Reincke M. Confirmatory testing in normokalaemic primary aldosteronism: the value of the saline infusion test and urinary aldosterone metabolites.  Eur J Endocrinol. 2006;  154 865-873
• 51 Gordon RD, Laragh JH, Funder JW. Low renin hypertensive states: perspectives, unsolved problems, future research.  Trends Endocrinol Metab. 2005;  16 108-113
• 52 Sealey JE, Gordon RD, Mantero F. Plasma renin and aldosterone measurements in low renin hypertensive states.  Trends Endocrinol Metab. 2005;  16 86-91
• 53 Olivieri O, Ciacciarelli A, Signorelli D, Pizzolo F, Guarini P, Pavan C, Corgnati A, Falcone S, Corrocher R, Micchi A, Cressoni C, Blengio G. Aldosterone to Renin ratio in a primary care setting: the Bussolengo study.  J Clin Endocrinol Metab. 2004;  89 4221-4226

Correspondence